Answers are grounded in this paper and cite their sources.
Objective Immune checkpoint inhibitors are increasingly used in elderly lung cancer patients, yet treatment response varies widely due to tumor immune microenvironment (TME) heterogeneity. This study aimed to develop a CT image-based deep learning model for TME risk stratification in elderly patients (≥ 60 years) and to explore the underlying imaging-transcriptomic mechanisms. Methods Transcriptomic and clinical data for 436 elderly lung cancer patients were obtained from TCGA, with matched CT images from TCIA. Tumor segmentation was performed using nnU-Net, followed by feature extraction via a 3D residual network. The DeepSurv model was constructed combining imaging features with clinical variables. Multi-omics analyses included differential expression, functional enrichment, immune microenvironment assessment (CIBERSORT/ESTIMATE/ssGSEA), WGCNA, and Lasso-Cox regression. External validation used ICGC and GEO immunotherapy datasets. Results The nnU-Net model achieved a Dice coefficient of 0.858. The DeepSurv fusion model attained a C-index of 0.748, outperforming clinical models (0.668). High-risk patients had significantly shorter median overall survival than low-risk patients (13.4 vs. 23.8 months, P < 0.001). A 12-gene signature was identified, enriched in extracellular matrix remodeling, TGF-β signaling, and epithelial-mesenchymal transition. The high-risk group exhibited increased M2 macrophage and regulatory T-cell infiltration with reduced CD8⁺ T cells, indicating an immunosuppressive phenotype. The signature stratified survival in the ICGC cohort (P = 0.002). Imaging-molecular correlation confirmed that imaging features reflect key immunosuppressive mechanisms. Conclusion This CT-based deep learning model effectively identifies elderly lung cancer patients with an immunosuppressive TME, offering superior risk stratification over traditional models. The imaging-molecular correlation supports CT imaging as a potential non-invasive tool for TME assessment and immunotherapy decision-making in elderly patients.
No takes yet. Share an insight, caveat, or question.
Han et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: